PHARM - Risperidone Pharmacokinetics in Children with Pervasive Developmental Disorder or Autism
Project Description:
This is a pharmacokinetic study looking at absorption and metabolism of risperidone (brand name: Risperdal) in young people. One goal is to collect information that will help researchers to develop a way to measure drug levels with fewer blood draws. In order to accomplish this, it is necessary to measure risperidone in blood plasma collected at specific times throughout a dosing interval.
Participants must be between the ages of 4 and 21, inclusive, and have been diagnosed with a pervasive developmental disorder (i.e., autism, asperger's) or a tic disorder. These individuals must be receiving treatment with risperidone.
Keyword(s):
Autism, Pervasive Developmental Disorder, Asperger's Disorder, Risperidone
Core Function(s):
Performing Research or Evaluation
Area of Emphasis
Health-Related Activities
Target Audience:
Children/Adolescents with Disabilities/SHCN
Unserved or Under-served Populations:
Specific Groups
Primary Target Audience Geographic Descriptor:
National
COVID-19 Related Data:
N/A